CYCLACEL PHARMACEUTICALS INC (CYCC)

US23254L6039 - Common Stock

0.67  +0.02 (+3.08%)

Full estimates are only available for subscribed users, you can see which data is available below.

Registered users have access to more data. Please register or login for additional estimates.

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates


2020 2021 2022 2023 2024 2025 2026
Revenue
EBITDA
-10.62M
-9.94%		-22.895M
-115.58%		-27.624M
-20.66%		N/AN/AN/AN/A
EBIT
-10.64M
-9.92%		-22.938M
-115.58%		-27.656M
-20.57%		-33.976M
-22.85%
Operating Margin
N/AN/AN/AN/A
EPS
-3.87
61.30%		-2.14
44.70%		-1.90
11.21%		-1.80
5.25%

All data in USD


Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates


Q2 / 23 Q3 / 23 Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS-0.51
-11.61%
RevenueN/AN/AN/AN/A
EBITDAN/AN/AN/AN/AN/AN/AN/A
EBIT-7.267M
-25.62%

All data in USD


EPS and Revenue Surprises


Recent Earnings VS Estimates (USD)
Period Reported Estimate Difference Surprise Q1 2023 -0.47 -0.68 0.2130.53% Q4 2022 -0.60 -0.49 -0.11-21.91% Q3 2022 -0.42 -0.57 0.1526.91% Q2 2022 -0.46 -0.64 0.1827.87% Q1 2022 -0.42 -0.70 0.2839.82% Q4 2021 -0.54 -0.67 0.1318.97% Q3 2021 -0.54 -0.66 0.1218.55% Q2 2021 -0.56 -0.51 -0.05-10.54%
Recent Revenue VS Estimates (USD)
Period Reported Estimate Difference Surprise Q1 2023 % Q4 2022 % Q3 2022 % Q2 2022 % Q1 2022 % Q4 2021 % Q3 2021 % Q2 2021 %

EPS and Revenue Revisions


Next Q (1 month)Next Q (3 month)Next Year (1 month)Next Year (3 month)
EPS7.36% -57.29% 0% 10.71%
RevenueN/A N/A N/A N/A